Mira partners with leading fertility clinics to optimize the treatment process and improve patient experience
Photo credit: unsplash
Incorporating Mira technology in the fertility treatment protocols will help to reduce the number of blood draws by 3 times leading to a significant reduction in in-person appointments, and optimizing the treatment process for both patients and fertility physicians.
Mira, an AI-powered at-home hormone monitoring device, collaborates with fertility clinics in the U.S., Canada, and Australia to make fertility care more accessible by reducing the number of patient visits and minimizing the costs of testing. With Mira devices, patients will be able to track their hormones from home with lab-grade accuracy, avoiding unnecessary clinic visits and invasive blood draws.
On average, 2 million infants born in the US each year are conceived through assisted reproductive technology. The demand for treatments such as in vitro fertilization (IVF) has doubled in the last decade. However, only 1 in 25 couples in the US have the access to the fertility care they need. In addition to this, fertility treatments are extremely stressful for the patient, let alone prohibitively expensive with the cost of a single IVF cycle ranging from $15,000 to $30,000.
Therefore, most of the leading fertility clinics have set out to simplify the treatments for the patient, make them more affordable, and get involved earlier in the patient journey. Technologies can help solve some of these problems by making the assisted fertility process smoother, less expensive, less invasive, and more comfortable for the patients.
The partnership between Mira and fertility clinics helps fertility physicians to scale up treatments and reduce the cost of testing while improving patient experience. Incorporating Mira in the IVF process allows for reducing the number of blood tests and in-person appointments by up to 3 times. It also enables fertility specialists to have real-time, around-the-clock access to the patient's hormone data and make data-driven decisions.
“In the post-Roe world, it’s more important than ever to democratize access to reproductive healthcare. Reproductive technology helps to make fertility care more accessible, less stressful, and less expensive while offering highly accurate and personalized results. At Mira, we’re excited to see more fertility specialists worldwide adopt our technology and understand the value it can provide to both clinicians and their patients,” says Sylvia Kang, CEO of Mira.
Mira has recently completed a trial with IVF patients in collaboration with Olive Fertility Center. The findings were presented at the American Society for Reproductive Medicine conference. The trial showed that urinary estrogen dynamics measured with Mira were found comparable to those measured with serum estrogen. This means using Mira for at-home urine monitoring can be a valuable alternative to blood tests for patients undergoing IVF. It's a huge step forward in making hormone tracking during fertility treatments more patient-friendly, convenient, and less intrusive.
Mira and Olive Fertility Center also plan on collaborating on a multicenter pilot to incorporate Mira in the natural-cycle frozen embryo transfer protocol. Olive Fertility Center has also recently started recommending Mira to their patients going through IUI.
"From my perspective as a reproductive endocrinologist and fertility specialist, Mira is a game-changing tool for patients and clinicians. With the convenience of home urine testing, the quantitative data of a laboratory blood test, and an informative and engaging app for hormone tracking — it seems to be the best of all worlds to improve the patient experience and optimize treatment outcomes. We are actively pursuing approaches to incorporate Mira into fertility treatments to reduce the burden of unnecessary blood tests and clinic visits.” - Dr. Gary Nakhuda, Reproductive Endocrinologist, co-founder, and medical director at Olive Fertility Center.
Mira is also working with Sama Fertility to help implement a more home-centric approach to fertility treatments. Experts at Sama have evaluated multiple solutions to replace blood tests while adding value for the patient and complementing their remote ovulation induction, IVF, and egg-freezing treatments. Trials show that Mira’s lab-grade accuracy is sufficient for making data-driven decisions about fertility treatments.
Genea is incorporating Mira in its clinical workflow to engage patients early in their journey. Proactive monitoring of patients’ hormone patterns allows their clinical team to make data-driven decisions about the patient's treatment plan. Additionally, Genea is planning a clinical trial to include Mira in the treatment protocols replacing blood draws or reducing them to a minimal number. The initiative will make the treatments simpler and less stressful for Genea’s patients.
With Mira’s technology being the only one on the market meeting the strict requirements of IVF treatment, Mira aims to create a new standard of daily, at-home hormone monitoring across the whole spectrum of fertility treatments.
ABOUT MIRA
Mira is the first at-home test to offer a personalized and lab-quality tracking system for monitoring women’s reproductive health. It uses patented AI algorithms to accurately measure the levels of major hormones in a woman’s urine to provide a holistic view of a woman’s reproductive health. Mira is FDA-compliant, clinically approved, and OB-GYN-recommended.
For more information on Mira, please visit miracare.com.
Press contact: | press@miracare.com|